I ran into an interesting article just as my EuroBio 'party' came to an end...
John Simons of Fortune recently reported that while biotech has led a charmed existence in the U.S. due to the complexity of its products, Congress and FDA are under pressure to create inexpensive biosimilars.
The European Commission seems to have already created a marketplace for generic biotech drugs. Last year, Novartis became the first company to gain approval (from the European Commission) to market a biosimilar - the human growth hormone, Omnitrope. The drug was later approved by the FDA upon special review.
Will Biotech follow Big Pharma in fighting to compete against generics?
For the full story click here.
MV
